Literature DB >> 28270396

Affording opportunities to discuss deterioration in paediatric palliative care consultations: a conversation analytic study.

Stuart Ekberg1, Susan Danby2, Anthony Herbert3, Natalie K Bradford3, Patsy Yates4.   

Abstract

OBJECTIVE: Discussing the potential deterioration of a child who has a life-limiting condition has recognised benefits for future care, but can be challenging in a clinical context where uncertain illness trajectories are common. Existing research is restricted to indirect forms of evidence such as self-report data from clinicians and families. This study directly explores how discussions about deterioration are managed within actual paediatric palliative care consultations.
METHODS: 9 consultations were video recorded in an Australian paediatric palliative care service. Each consultation involved the same paediatric palliative care specialist. Conversation analysis was used to identify and explore recurrent ways in which discussions about deterioration came to be realised.
FINDINGS: The study identified two communicative practices used by a paediatric palliative care specialist that afforded opportunities to discuss deterioration: (1) soliciting the family's agenda for the consultation; (2) initiating and maintaining topics where discussing deterioration is a relevant possibility. Across these different practices, a common feature was indirect initiation of discussions about deterioration. This approach made such discussions possible, but without mandating or even suggesting that such discussion must occur.
CONCLUSIONS: These communicative practices balance the benefit of discussing deterioration against a recognised importance of allowing discussions to be directed by a child's family. This was achieved by creating opportunities for discussing deterioration, without making such discussions necessary. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Communication; Family management; Paediatrics; Prognosis

Year:  2017        PMID: 28270396     DOI: 10.1136/bmjspcare-2016-001130

Source DB:  PubMed          Journal:  BMJ Support Palliat Care        ISSN: 2045-435X            Impact factor:   3.568


  6 in total

1.  Physician decision-making process about withholding/withdrawing life-sustaining treatments in paediatric patients: a systematic review of qualitative evidence.

Authors:  Yajing Zhong; Alice Cavolo; Veerle Labarque; Chris Gastmans
Journal:  BMC Palliat Care       Date:  2022-06-24       Impact factor: 3.113

2.  Communication between healthcare professionals and relatives of patients approaching the end-of-life: A systematic review of qualitative evidence.

Authors:  Rebecca J Anderson; Steven Bloch; Megan Armstrong; Patrick C Stone; Joseph Ts Low
Journal:  Palliat Med       Date:  2019-06-11       Impact factor: 4.762

Review 3.  Communicating with patients and families about illness progression and end of life: a review of studies using direct observation of clinical practice.

Authors:  Stuart Ekberg; Ruth Parry; Victoria Land; Katie Ekberg; Marco Pino; Charles Antaki; Laura Jenkins; Becky Whittaker
Journal:  BMC Palliat Care       Date:  2021-12-08       Impact factor: 3.234

4.  Attending to child agency in paediatric palliative care consultations: Adults' use of tag questions directed to the child.

Authors:  Katie Ekberg; Stuart Ekberg; Lara Weinglass; Anthony Herbert; Johanna Rendle-Short; Myra Bluebond-Langner; Patsy Yates; Natalie Bradford; Susan Danby
Journal:  Sociol Health Illn       Date:  2022-01-28

5.  National Divergences in Perinatal Palliative Care Guidelines and Training in Tertiary NICUs.

Authors:  Antonio Boan Pion; Julia Baenziger; Jean-Claude Fauchère; Deborah Gubler; Manya J Hendriks
Journal:  Front Pediatr       Date:  2021-07-14       Impact factor: 3.418

Review 6.  Palliative Care in Paediatric Oncology: an Update.

Authors:  Naveen Salins; Sean Hughes; Nancy Preston
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.